CTOs on the Move

Medac Corporation

www.medac.com

 
Medac Corporation is a Augusta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.medac.com
  • 804 Scott Nixon Memorial Dr
    Augusta, GA USA 30907
  • Phone: 706.650.0705

Executives

Name Title Contact Details
Sam Bruce
Chief Information Security Officer Profile

Similar Companies

Sara Wasserbauer M.D.

Hair Transplant Surgery and medical hair loss treatments by hair surgeon Sara Wasserbauer, M.D.. Medical Hair Restoration services. Medical Hair Loss Treatments, in Walnut Creek, San Jose, San Francisco and Napa, California.(CA)

OPEN Health

We provide deep scientific knowledge, global understanding and broad expertise to enhance market access and medical communications for improved health outcomes.

21st Century Biochemicals

21st Century Biochemicals is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ColoWrap

ColoWrap is the first clinical colonoscopy compression device that prevents the need for manual abdominal pressure and patient repositioning during colonoscopy.

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.